Page 198 - Drug Class Review
P. 198

Page 129 of 205
             Drug Effectiveness Review Project




























































                          Alzheimer Drugs     Authors: Schneider et al.; 35  Potkin et al.; 74  Burns et al. 75    Year: 1998; 2002; 2004   Country: Multinational   Novartis Pharmaceutical   Study design: Meta-analysis  Number of patients: 2,126  To assess the efficacy of RIV in patients with mild to moderately severe probable AD.     Three RCTs (2 published Rosler 1998, Corey-Bloom 1998; 1 unpublished)   NR  Randomized, controlled, double-blinded trials with 26 weeks study durations. Unpublished trial was fixed  dose (3mg, 6mg, 9mg); published trials partially flexible (1-4mg, 6-12mg)  Patients with mild to moderately sever

























             Final Report Update 1     Efficacy/Effectiveness      STUDY:      FUNDING:      DESIGN:          AIMS OF REVIEW:   STUDIES INCLUDED IN   META-ANALYSIS     TIME PERIOD COVERED:     CHARACTERISTICS OF  INCLUDED STUDIES:     CHARACTERISTICS OF  INCLUDED POPULATIONS:           Alzheimer's Drugs
   193   194   195   196   197   198   199   200   201   202   203